RealFeedApp beta
- Novo and Lilly present early longevity data
Novo Nordisk and Eli Lilly presented data showing reduced mortality and improved physical function in a cohort of 19,117 participants from the SELECT trial.
- Field
- ageing and longevity
- What they did
- Novo Nordisk and Eli Lilly presented preliminary data suggesting that GLP-1 drugs (including semaglutide) may reduce mortality and improve physical function, which models predict could lead to increased life expectancy.
- Why it matters
- This information will help determine how effectively these drugs can extend healthy life and could serve as a basis for future clinical trials.
#glp-1#semaglutide#longevity#select trial
